Accelerated Sales of HALB's Patented Products through newly formed “The Hamden Group” Jackson Center, PA, November 14, 2022 – Halberd Corporation (OTC-PINK: HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists of members of the Croden family and Darren Hamans, who have extensive experience in the ...
Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”. The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease ...
Jackson Center, PA, August 04, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd’s research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players. Traumatic brain injuries ...
Jackson Center, PA, July 20, 2022 – Halberd Corporation (OTC-PINK: "HALB”) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd’s patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. For now, the new entity will be staffed by Halberd personnel ...
Q2 Accomplishments and a Look to the Future Jackson Center, PA, July 12, 2022. Halberd Corporation (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows: 2Q ACHIEVEMENTS Added an animal testing expert (DVM/PhD) ...
Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...
Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes. Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi ...
Jackson Center, PA, May 24, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid. Several adverse health conditions are caused by excess quantities of particular components in blood or ...
Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...
Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states. The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes. This ...